Search results
Showing 1501 to 1550 of 2051 results for work
Evidence-based recommendations on lutetium (177Lu) oxodotreotide (Lutathera) for treating unresectable or metastatic neuroendocrine tumours in adults.
Omalizumab for treating severe persistent allergic asthma (TA278)
Evidence-based recommendations on omalizumab (Xolair) for treating severe persistent allergic asthma in people aged 6 and over.
Evidence-based recommendations on durvalumab (Imfinzi) with tremelimumab (Imjudo) for untreated advanced or unresectable hepatocellular carcinoma in adults.
Dimethyl fumarate for treating moderate to severe plaque psoriasis (TA475)
Evidence-based recommendations on dimethyl fumarate (Skilarence) for treating moderate to severe plaque psoriasis in adults.
Digital technologies to support self-management of COPD: early value assessment (HTG736)
Early value assessment (EVA) guidance on digital technologies to support self-management of COPD.
Evidence-based recommendations on tixagevimab plus cilgavimab (Evusheld) for preventing COVID-19 in adults.
Evidence-based recommendations on exagamglogene autotemcel (Casgevy) for transfusion-dependent beta-thalassaemia in people 12 years and over.
Ledipasvir–sofosbuvir for treating chronic hepatitis C (TA363)
Evidence-based recommendations on ledipasvir–sofosbuvir (Harvoni) for treating some types (genotypes) of chronic hepatitis C.
This guideline covers identifying and caring for adults who are malnourished or at risk of malnutrition in hospital or in their own home or a care home. It offers advice on how oral, enteral tube feeding and parenteral nutrition support should be started, administered and stopped. It aims to support healthcare professionals identify malnourished people and help them to choose the most appropriate form of support.
NICE has developed a medtech innovation briefing (MIB) on AlignRT in breast cancer radiotherapy .
Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]
In development Reference number: GID-TA10592 Expected publication date: TBC
Adrenal insufficiency: identification and management (NG243)
This guideline covers identifying and managing adrenal insufficiency (hypoadrenalism) in babies, children, young people and adults. It aims to improve the treatment of primary, secondary and tertiary adrenal insufficiency, and the prevention and management of adrenal crisis.
Discontinued Reference number: GID-TA10739
Discontinued Reference number: GID-IP1156
Dasatinib for the treatment of acute lymphoblastic leukaemia [ID386]
Discontinued Reference number: GID-TAG399
Evidence-based recommendations on apremilast (Otezla) for treating active psoriatic arthritis.
Relugolix–estradiol–norethisterone for treating symptoms of endometriosis (TA1057)
Evidence-based recommendations on relugolix–estradiol–norethisterone (Ryeqo) for treating symptoms of endometriosis in adults of reproductive age.
Show all sections
In development Reference number: GID-TA10780 Expected publication date: TBC
Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]
In development Reference number: GID-TA11228 Expected publication date: TBC
Masitinib for previously treated moderate Crohn's disease [ID1239]
Discontinued Reference number: GID-TA11188
Discontinued Reference number: GID-TA11206
Discontinued Reference number: GID-TA11207
Ovarian (epithelial), fallopian, peritoneal cancer - paclitaxel (encapsulated in XR-17 [ID565]
Discontinued Reference number: GID-TA11209
Multiple myeloma (untreated) - carfilzomib (with melphalan and prednisone) [ID1133]
Discontinued Reference number: GID-TA11210
In development Reference number: GID-TA11689 Expected publication date: TBC
Deucravacitinib for treating moderate to severe plaque psoriasis (TA907)
Evidence-based recommendations on deucravacitinib for treating moderate to severe plaque psoriasis in adults.
This quality standard covers prevention of falls and assessment after a fall in people who are living in the community, in a residential care setting or staying in hospital and are:
View quality statements for QS86Show all sections
Sections for QS86
- Quality statements
- Quality statement 1: Asking people about falls
- Quality statement 2: Comprehensive falls assessment
- Quality statement 3: Interventions to reduce the risk of falls
- Quality statement 4: Checks for injury after an inpatient fall
- Quality statement 5: Safe manual handling after an inpatient fall
- Quality statement 6: Medical examination after an inpatient fall
- Quality statement 7: Multifactorial risk assessment for older people presenting for medical attention
Ibrutinib for treating relapsed or refractory follicular lymphoma and marginal zone lymphoma [ID977]
Discontinued Reference number: GID-TA11238
In development Reference number: GID-TA11345 Expected publication date: TBC
Bone loss (therapy-induced) in non-metastatic breast cancer - denosumab [ID83]
Discontinued Reference number: GID-TAG411
Hypoglossal nerve stimulation for moderate to severe obstructive sleep apnoea (HTG455)
Evidence-based recommendations on hypoglossal nerve stimulation for moderate to severe obstructive sleep apnoea in adults. This involves implanting a device under the skin in the chest and connecting it to a nerve under the tongue (hypoglossal nerve).
MRI-based technologies for assessing non-alcoholic fatty liver disease (HTG655)
Evidence-based recommendations on MRI-based technologies for assessing non-alcoholic fatty liver disease.
Neuroblastoma (high-risk) - dinutuximab (maintenance, after therapy) [ID799]
Discontinued Reference number: GID-TAG507
Evidence-based recommendations on avacopan (Tavneos) for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis in adults.
Discontinued Reference number: GID-IP267
Dexmedetomidine for treating agitation associated with schizophrenia TS ID 10726
In development Reference number: GID-TA11015 Expected publication date: TBC
In development Reference number: GID-TA11014 Expected publication date: TBC
Evidence-based recommendations on fenfluramine (Fintepla) for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over.
In development Reference number: GID-TA11104 Expected publication date: TBC
Atrial fibrillation - clopidogrel (in combination with aspirin) [ID95]
Discontinued Reference number: GID-TAG416
In development Reference number: GID-TA11679 Expected publication date: TBC
In development Reference number: GID-TAG406 Expected publication date: TBC
In development Reference number: GID-TA10483 Expected publication date: TBC
Extra corporeal membrane oxygenation for acute heart failure in children
Discontinued Reference number: GID-IP1153
Galaxy UNYCO for temporary stabilisation of lower limb fractures (MIB166)
NICE has developed a medtech innovation briefing (MIB) on Galaxy UNYCO for temporary stabilisation of lower limb fractures .
NICE has developed a medtech innovation briefing (MIB) on PIUR tUS for abdominal aortic aneurysm surveillance and endovascular aneurysm repair endoleak detection .
NICE has developed a medtech innovation briefing (MIB) on Lifelight First for monitoring vital signs .
Discontinued Reference number: GID-TAG390
Intensity modulated radiotherapy for head and neck cancer [ID15]
Discontinued Reference number: GID-TAG397
Discontinued Reference number: GID-TAG396